Prospect News: News for Sanofi-Aventis SA

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

User:

Log out

Prospect News home > Main news index > All issuers starting with S > All stories on Sanofi-Aventis SA

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Sanofi-Aventis SA

2/10/2016	SP	RBC plans buffered return optimization notes linked to European stocks
4/16/2015	SP	New Issue: Barclays prices $1.38 million seven-year notes linked to basket of ADSs
4/1/2011	IG	Market Commentary: BNP Paribas closes out busy week of new deals; Archer Daniels, Verizon, Sanofi-aventis firmer
3/31/2011	IG	Market Commentary: Campbell's, Macquarie, Asciano hit market; Q1 breaks records; selling active in new bonds
3/29/2011	IG	Market Commentary: Time Warner, Citi, HSBC sell as large deals dominate; new bonds trade mixed as some widen
3/28/2011	IG	Market Commentary: Dell, Home Depot start week with big trades; trading slows after heavy week, Sanofi active
3/24/2011	IG	Market Commentary: Viacom sells bonds as recent influx of new deals is absorbed; Wal-Mart widens, telecoms firm
3/23/2011	IG	New Issue: Sanofi-aventis' $7 billion note sale for Genzyme acquisition detailed
3/23/2011	IG	Market Commentary: Verizon follows Sanofi with mega-deal, Gilead, Caterpillar price; new bonds firm 1 bp-2 bps
3/22/2011	IG	New Issue: Sanofi-aventis sells jumbo $7 billion deal to fund Genzyme acquisition
3/22/2011	IG	Market Commentary: Sanofi, DuPont, Wells Fargo lead issuers with huge deals; AT&T, Verizon better; Sprint down
2/16/2011	SP	New Issue: RBC prices $1.06 million 9.4% reverse convertibles linked to Sanofi
2/1/2011	IG	S&P: sanofi-aventis on watch
1/24/2011	SP	RBC plans 8.5%-13% six-month reverse convertibles on Sanofi-Aventis
10/4/2010	IG	Moody's may cut sanofi-aventis
8/31/2010	IG	Fitch: Sanofi-Aventis view negative
3/15/2010	CVIG	Sanofi-aventis files automatic shelf registration for debt securities
12/21/2009	BKBWCVHY	Chattem's outstanding debt to be assumed by Sanofi via acquisition
8/7/2009	SS	Market Commentary: Merck awaits end of reviews; IPC buyout may hinge on weather; FTC clears Watson Wyatt merger
7/30/2009	IG	Fitch affirms Sanofi-Aventis
4/23/2009	SS	Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
2/2/2009	SS	Market Commentary: Second Amylin shareholder wants changes; analysts predict higher bid for CV Therapeutics
1/9/2009	SS	Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
2/12/2007	SS	Market Commentary: Four Seasons, Hilton, Starwood slide; Southwest soars; Eddie Bauer off; WCI up; Onyx rockets
1/29/2007	SS	Market Commentary: Bristol-Myers up; Harrah's slips; First Bancorp, Doral, W Holding up; Sea Containers slides; Delta better
10/31/2006	BT	Sanofi-aventis third quarter affected by generic launch, net sales down 1.1%
10/25/2006	BT	Market Commentary: Cadence rises after pricing below range; ImClone dips, ends up 5%; PDI off by 4%; Arena rebounds 7%
9/26/2006	BT	Sanofi-Aventis starts cell culture-based seasonal flu vaccine trial
9/25/2006	BT	UCB, Sanofi to co-promote antihistamine Xyza in United States
9/21/2006	BT	Court upholds injunction against Apotex's generic Plavix
9/20/2006	BT	Sanofi pasteur starts C$30 million capital expansion at Toronto manufacturing site
9/19/2006	BT	Sanofi Pasteur starts clinical trial of PER.C6-based H7N1 vaccine
9/8/2006	BT	Sanofi-Aventis' Lovenox is safer than standard of care, study says
9/7/2006	BT	Sanofi-Aventis, Bristol-Myers get expanded European Plavix indication, withdraw dronedarone
9/7/2006	BT	Sanofi-Aventis: enoxaparin reduces bleeding after PCI treatment
9/5/2006	BT	Sanofi-Aventis: New data show enoxaparin reduces risk of repeat heart attacks, stroke in some patients
9/1/2006	BT	Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
9/1/2006	BT	Injunction halts Apotex sales of generic Plavix in Sanofi-Aventis, Bristol-Myers Squibb patent case
8/31/2006	BT	ImmunoGen, Sanofi-Aventis extend cancer drug research collaboration
8/30/2006	BT	Fitch affirms Sanofi-Aventis
8/17/2006	BT	Sanofi-Aventis, Bristol-Myers' Plavix gets FDA approval for new indication
8/14/2006	BT	Sanofi-Aventis, Bristol Myers Squibb file motion to stop sales of Apotex' generic Plavix
8/9/2006	BT	Fitch: sanofi-aventis can absorb Plavix sales loss
8/8/2006	BT	Sandoz', Momenta's generic Lovenox challenged by Aventis
8/8/2006	BT	S&P: Sanofi-Aventis unchanged
8/8/2006	BT	Market Commentary: Barrier loses 13%; Teva up more than 5%; Antigenics comes off highs; Amylin falls 7%
8/8/2006	BT	Apotex launches generic Plavix; Bristol-Myers Squibb, sanofi-aventis mull legal options
8/3/2006	BT	Amgen erythropoietin patents infringed upon by Transkaryotic, Aventis, court says
7/28/2006	BT	Bristol-Myers, sanofi fail to receive anti-trust clearance for Plavix settlement
7/27/2006	BT	Bristol-Myers, sanofi say Apotex litigation settlement is under criminal investigation
7/12/2006	BT	Sanofi data supports Ambien use for up to six months
6/21/2006	BT	Sanofi-Aventis receives European marketing approval for obesity drug
6/20/2006	BT	Sanofi-Aventis: Enoxaparin results in significant savings compared to unfractionated heparin
6/12/2006	BT	Sanofi-Aventis study shows algorithm as effective as mealtime insulin dosing in type 2 diabetes
6/6/2006	BT	Sanofi-Aventis: Eloxatin-based regimens extend survival beyond two years in colorectal cancer
6/5/2006	BT	Phase 3 safety, efficacy data shows bone mineral increase in risedronate-treated male osteoporosis patients
6/5/2006	BT	Sanofi meta-analysis shows benefits of Taxotere
5/16/2006	BT	Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
5/11/2006	BT	Sanofi pasteur: H5N1 flu vaccine candidate demonstrates significant immune response
5/5/2006	BT	Sanofi-Aventis: net sales up 4.9%, operating income increases 37.4%
5/4/2006	BT	Barr to challenge Aventis' Nasacort patent
4/10/2006	BT	Sanofi-aventis to construct new R&D facility in Arizona
3/24/2006	BT	Sanofi gets positive European opinion on Taxotere for stomach cancer
3/23/2006	BT	Sanofi-Aventis's Taxotere gets FDA OK for treatment of stomach cancer
3/22/2006	BT	Sanofi-Aventis at peer perform by Bear Stearns
3/22/2006	BT	Sanofi-Aventis at underperform by Credit Suisse
3/22/2006	BT	Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
3/21/2006	BT	Sanofi-Aventis, Bristol-Myers settle Plavix litigation with Apotex
3/20/2006	BT	Sanofi-Aventis reaffirms safety profile of Ambien in response to media reports
3/16/2006	BT	Sanofi-Aventis to produce shikimic acid for Roche's Tamiflu
3/13/2006	BT	Study shows no benefit of adding Plavix, Iscover to aspirin therapy to reduce risk of heart attack
3/7/2006	BT	Injunction suspends QLT, Sanofi sales of Eligard in United States until TAP patent expires
2/28/2006	BT	King, Aventis, Cobalt agree to dismiss Altace patent litigation
2/28/2006	BT	Moody's ups Sanofi-Aventis outlook to positive
2/17/2006	BT	Sanofi-aventis receives approvable letter for rimonabant for weight control, non-approvable for smoking
2/6/2006	BT	Sanofi pasteur delivers more H5N1 vaccine for U.S. government pandemic initiatives
1/18/2006	BT	Sanofi-aventis granted FDA priority review for Plavix application
1/18/2006	BT	Sanofi, Bristol-Myers seek FDA approval of new indication for Plavix
12/21/2005	BT	Sanofi pasteur licenses micro-delivery technology from Becton, Dickinson for use with vaccines products
12/15/2005	BT	Sanofi pasteur's adjuvanted avian flu vaccine efficacious, study says
12/13/2005	BT	Bristol-Myers, sanofi's Plavix recommended for peripheral arterial disease
12/8/2005	BT	sanofi says results of phase 3 Herceptin study in breast cancer show improved disease-free survival
12/2/2005	BT	Sanofi-aventis gets FDA priority review for Taxotere gastric cancer drug
11/28/2005	BT	Marshall Edwards, Sanofi-Aventis plan trial of phenoxodiol with docetaxel for ovarian cancer
11/9/2005	BT	Fitch gives Sanofi-Aventis AA- senior rating
10/31/2005	BT	Enzon reduces royalty payments to Sanofi-Aventis for oncology treatment Oncaspar
10/31/2005	BT	Sanofi pasteur to license adjuvant from Eisai
10/28/2005	BT	Exubera FDA review pushed back, says Pfizer and sanofi-aventis
9/8/2005	BT	Sanofi-Aventis kept by Bear at outperform
9/7/2005	BT	Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
9/1/2005	BT	Sanofi-Aventis maintained by Deutsche Bank at hold
8/26/2005	BT	Sanofi-Aventis assigned market perform by Leerink Swann

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.